Abstract
The fields of medicine and therapeutics have lately turned towards more modern approaches for the therapy of diseases. These approaches have been classified as new health technologies and various issues that regard their development, application in therapy, regulatory framework, approval and post-approval monitoring have emerged. In the European environment, the law and legislation distinguish new health technologies in certain subcategories, namely, medicinal products, medical devices, biotechnological products, advanced therapy medicinal products and nanomedicinal products. Among these strategies, nanomedicine utilizes entities at the nanoscale that exhibit therapeutic effect in various diseases, such as neurodegenerative disorders, through chemical, physical or biological action. Several nanotechnology-based therapies have been authorized until today; however, there is still no marketed nanomedicine for neurodegenerative diseases. Advanced nanotechnological platforms, including the prominent example of stimuli-responsive chimeric/mixed nanocarriers, promise high therapeutic efficacy and safety, through their functional properties and biocompatibility, which come from their composing molecules, self-assembled properties and supramolecular structures. The integration of certain important analytical tools for the study of nanocarriers is also of great importance and may provide knowledge for further development of advanced nanomedicines as well as for their follow-on products, known as “nanosimilars”.
You have full access to this open access chapter, Download conference paper PDF
Similar content being viewed by others
The fields of medicine and therapeutics have lately turned towards more modern approaches for the therapy of diseases. These approaches have been classified as new health technologies and various issues that regard their development, application in therapy, regulatory framework, approval and post-approval monitoring have emerged. In the European environment, the law and legislation distinguish new health technologies in certain subcategories, namely, medicinal products, medical devices, biotechnological products, advanced therapy medicinal products and nanomedicinal products. Among these strategies, nanomedicine utilizes entities at the nanoscale that exhibit therapeutic effect in various diseases, such as neurodegenerative disorders, through chemical, physical or biological action. Several nanotechnology-based therapies have been authorized until today; however, there is still no marketed nanomedicine for neurodegenerative diseases. Advanced nanotechnological platforms, including the prominent example of stimuli-responsive chimeric/mixed nanocarriers, promise high therapeutic efficacy and safety, through their functional properties and biocompatibility, which come from their composing molecules, self-assembled properties and supramolecular structures. The integration of certain important analytical tools for the study of nanocarriers is also of great importance and may provide knowledge for further development of advanced nanomedicines as well as for their follow-on products, known as “nanosimilars”.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Naziris, N., Demetzos, C. (2021). Advanced Health Technologies and Nanotechnologies in Neurodegenerative Diseases. In: Vlamos, P. (eds) GeNeDis 2020. Advances in Experimental Medicine and Biology, vol 1339. Springer, Cham. https://doi.org/10.1007/978-3-030-78787-5_37
Download citation
DOI: https://doi.org/10.1007/978-3-030-78787-5_37
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-78786-8
Online ISBN: 978-3-030-78787-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)